Menu
View Cart  

Recommended Products

Visit Store
Gmp-inspection-preparation-checklist-130x160

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological-risk-eval-and-mngmnt-for-md-130x160

Biological Risk Evaluation and Management for Medical Devices

Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Events

View All
Nov 14

Conducting Advanced Root Cause Analysis and CAPA Investigations

Nov 14

Clinical Trial Risk and Performance Management Summit

Nov 28

REMS: Requirements, Regulation, and Enforcement — Evolution from Safety Program to Enforcement Tool

Nov 29

Chinese Medicine: The Dangers of Deployment — The Impact on Pharmaceutical Regulatory and…

Dec 4

FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

Dec 5

Laboratory Developed Tests, In Vitro Diagnostics & Gene Therapies: DAIA Will be a Game-Changer

Editor's Picks

View all
Abbott-logo

NHS England Picks Up Glucose Monitors for Type 1 Diabetes Patients

The devices are now available on prescription for all patients that qualify through NHS’ clinical guidelines.
Grey_approved_stamp

FDA Expands Approval of Bristol-Myers Squibb’s Empliciti

EPd is the first triplet combination approved based on a randomized clinical trial using pomalidomide and dexamethasone as comparators.
FDAnews Drug Daily Bulletin

RANBAXY CONSOLIDATES RELATIONSHIP WITH JAPAN JV PARTNER NIPPON CHEMIPHAR

Nov. 14, 2005
KEYWORDS FDAnews Drug Daily Bulletin
A A

Ranbaxy Laboratories Limited on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry Co Ltd (NPI), a joint-venture between the company and Nippon Chemiphar Co Ltd (NC), Japan from the present 10 per cent. With this enhancement, NPI will become a 50:50 JV between the two companies, a statement by Ranbaxy said. An agreement in this regard has been signed on Friday, it added.

Hindustan Times (http://www.hindustantimes.com/news/181_1543183,00020009.htm)